Skip to content
DataLookout
Menu

NCT07927036

Enhancing the Effect of Stellate Ganglion Block in the Treatment of PTSD: Bupivacaine vs Bupivacaine + Ketamine

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Interventions modified
    • Secondary endpoints revised (4)
    • Study title shortened, about 8 words
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Change of the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity score
Timeframe: From baseline to +4 weeks

Secondary (3)

The mean change in PTSD Check List-5 (PCL-5) scores
Proportion of patients achieving reliable change (at least 14-point reduction) in the total score on Outcome Questionnaire 45 (OQ45)
Changes in participant's symptomatology and overall functioning from the perspective of the participant's family and support network measured by the Family and Support Team Questionnaire (FAST-Q)

Arms and interventions

Group 1: One SGB injection combining standard local anesthetic, bupivacaine, with salineActive comparator

One dose of 6mL 0.5% bupivacaine combined with 2ml normal saline. The dose and medication provided to Group 1 is in line with current research practice for SGB which suggests a dosage between 6mL and 9 mL of local anaesthetic. Saline is included in the injection to match the volume of the injection for Group 2 without adding additional medical properties to the solution.

Group 2: One SGB injection combining standard local anesthetic, bupivacaine, with KetamineExperimental

The bupivacaine dose administered to Group 2 is identical to that administered to Group 1, with the addition of 20 mg ketamine (2 mL of a 10 mg/mL solution). A fixed ketamine dose of 20 mg was selected to approximate a low-dose (subanesthetic) exposure of 0.3 mg/kg in a 70 kg adult (21 mg), while allowing standardized dosing across participants. This dose was chosen to remain within a range commonly used in clinical research investigating the analgesic and neuropsychiatric effects of ketamine. This is the accepted standard and widely used dose in clinical practice.

Group 3: Treatment as usualNo intervention

Participants selected to this group will not receive any intervention and continue with their treatments as usual.

Combination products: SGB - Combined Solution of Bupivacaine + Saline, SGB - Combined Solution of Bupivacaine + Ketamine Adjuvant

Sites

1 site in 1 country

  • The RoyalOttawa, Ontario, Canada